← board
IOBTQ
IO Biotechdistress 5/10 · elevated risk$0.00-67%today-100% from 52w high
Oncology 4Immunology / Inflammation 1
Lead: advanced melanoma · target PD-1 · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$31M
Runway
0.4 yrs
Shares 1y
+9%
Price & events
-99.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-66.7%
1D
-80.0%
1W
-83.3%
1M
-85.7%
3M
-99.8%
6M
-99.9%
1Y
-99.9%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $71.95K
- Enterprise Value
- $-13.93M
- Volume
- 16.70K
- 52 Week Range
- $0.00 – $2.40
- Total Shares
- 71.95M
- Float Shares
- 49.67M
- Short %
- 7.49%
- % Held by Insiders
- 0.31%
- % Held by Institutions
- 34.77%
- RVOL
- 0.05x
- Beta
- -0.17
Pipeline stages · 2 programs
IO102-IO103 in combination with pembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IRX4204
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03 | Phase 2 | IRX4204 | Psoriasis, Plaque Type Psorisis, Plaque Psoriasis | 20 | suspended |
| 2025-11-30 | Phase 2 | IO102-IO103 in combination with pembrolizumabbreakthrough | Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder | 63 | completed |
| 2025-05-30 | Phase 3 | IO102-IO103, Pembrolizumabbreakthrough | Metastatic Melanoma, Unresectable Melanoma | 407 | active not recruiting |
| 2025-05-09 | Phase 1 | IRX4204, erlotinib | Lung Cancer, Nonsmall Cell | 12 | terminated |
| 2025-04-30 | Phase 2 | IO102-IO103, Pembrolizumab KEYTRUDA®breakthrough | Melanoma, Squamous Cell Carcinoma of Head and Neck | 60 | recruiting |
Catalyst news & presentations · 8
- 6 to 9 monthsreadoutPhase 3Cylembio (imsapepimut and etimupepimut, adjuvanted) · OS data maturation expectedSEC 8-K
- 2026-03-31withdrawalFiled Chapter 7 bankruptcy and ceased operationsSEC 8-K
- by year end 2025regulatory submissionFiled (NDA/BLA)Cylembio · BLA submission to FDASEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)IO112 · IND submission to FDASEC 8-K
- second half of 2025readoutPhase 2Cylembio · Longer-term follow-up dataSEC 8-K
- third quarter of 2025readoutPhase 3Cylembio · Primary endpoint PFS readoutSEC 8-K
- 2025-09-29refuse to fileCylembio · FDA recommended that the Company not submit a BLA based on data from IOB-013 trial.SEC 8-K
- first half of 2025readoutPhase 3IO102-IO103 · Primary endpoint PFS readoutSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-01-26Piper SandlerOverweight → Neutral
- 2025-10-22Piper SandlerOverweight
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- TNGXTango Therapeutics, Inc.$4.0B · D5
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
Recent news
- 2026-07-07Price to sales forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
- 2026-07-07Price to earnings forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
- 2026-06-25IO Biotech, Inc. Actuals & Estimates (OTC:IOBTQ) - TradingView
- 2026-04-09What is the current Price Target and Forecast for IO Biotech, Inc. (IOBTQ) - Zacks Investment Research
- 2026-04-08IOBTQ Stock Price and Chart — OTC:IOBTQ - TradingView
- 2026-04-07U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.18% - Investing.com
- 2026-03-24What’s ahead in ophthalmology: Pipeline milestones for Q2 2026 - Ophthalmology Times Europe
- 2026-02-23Breaking: Gilead Doubles Down on CAR T with $7.8B Acquisition of Arcellx - BioBuzz
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.